Right now, that's none other than Eli Lilly (NYSE: LLY). However, others are looking to challenge its dominance. Recent ...

CEO Albert Bourla sits down with Yahoo Finance Executive Editor Brian Sozzi to talk about when consumers can expect to see ...

At a price of up to $10 billion, Pfizer has claimed victory in its bidding war against Novo Nordisk to acquire Metsera. It's ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

Pfizer (PFE) managed to outbid competitor Novo Nordisk (NVO) to acquire Metsera (MTSR) in a deal valued at up to $10 billion. Pfizer stock is down by nearly 3% from this time a year ago. Robinhood ...

Pfizer Inc. Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma ...

Pfizer Inc. Chief Executive Albert Bourla said the company secured a three-year grace period from President Trump’s promised tariffs on pharmaceuticals in a deal that would lower some of the company’s ...

The GLP-1 agonist at the center of Pfizer’s upfront $4.9 billion buyout of Metsera last week has been tied to 14.1% weight loss at 28 weeks as well as “potentially class-leading tolerability,” ...

Pfizer has won the week-long bidding war for Metsera with an upwardly revised up-to-$10 billion offer matching that of rival Novo Nordisk—and more than a little help from Washington.

US drugmaker Pfizer said Thursday that it has completed its acquisition of biotech firm Metsera, closing a deal worth up to ...

Pfizer CEO Albert Bourla appeared on ABC's "This Week." Pfizer CEO Albert Bourla said on ABC's "This Week" Sunday it's possible to provide both COVID-19 booster shots as well as doses for people who ...

By Mariam Sunny (Reuters) -Shares of Metsera fell over 15% in early trading on Monday, after the weight-loss drug developer ...